Antitumor Activity Observed at Interim Analysis of Phase 2 MANTRA-2 Basket Trial of Milademetan in Advanced Solid Tumors

Article

Patients with advanced solid tumors treated with milademetan experienced promising anti-tumor activity at the interim analysis for the phase 2 MANTRA-2 basket trial.

Updated results from the phase 2 MANTRA-2 basket trial (NCT05012397) identified promising preliminary antitumor activity for patients with MDM2-amplified advanced tumors who received milademetan, according to a press release Rain Therapeutics.

At the data cutoff of October 26, 2022, 17 patients were enrolled. Two unconfirmed partial responses were observed in patients with pancreatic and lung cancer with a tumor regression of 34% and 30% with lung cancer, respectively. Additionally, there was promising tumor regression of 29% in a patient with biliary tract cancer and 27% in a patient with breast cancer; both are receiving continued investigational therapy.

Milademetan is an oral inhibitor of the MDM2-p53 complex that helps to reactivate p53. The agent has previous shown antitumor activity within a subgroup of patients with MDM2-amplified liposarcoma and other solid tumors, according to phase 1 research.

“We are encouraged by the preliminary observations from the MANTRA-2 trial,” Avanish Vellanki, co-founder and chief executive officer of Rain, said in the press release. “Treatment with milademetan led to tumor regression in patients previously treated with a multitude of therapies across a range of cancers. We look forward to expanding this dataset as the trial continues to enroll.”

Of the patients enrolled on the trial, 15 have been treated with milademetan. Overall, 10 patients were evaluable for efficacy with a copy number of 8 or more by central testing. All patients had diverse tumor histologies, with most tumors having co-alterations in oncogenes or tumor suppressors in KRAS, EGFR, and PIK3CA. Patients were treated with milademetan at an oral dose of 260 mg once daily on days 1 to 3 and 15 to 17 of each 28-day cycle.

The primary end point of the trial was overall response rate, with secondary end points including duration of response, progression-free survival, growth modulation index, disease control rate, and overall survival.

Anti-tumor activity was observed on patients who were heavily pretreated or refractory with a median of 4 prior therapies. The safety profile remained consistent with previously reported phase 1 findings.

To be eligible for treatment, patients were required to have histologically or cytologically confirmed disease, measurable lesions, and have received standard therapy appropriate for tumor type and stage. There also needed to be a resolution to any clinically relevant toxic effects, a presence of wild-type TP53 and MDM2 gene amplification by tumor testing. Additionally, patients needed an ECOG performance status of 0 or 1, and adequate bone marrow, renal, and hepatic function.

Exclusion criteria included having prior treatment with an MDM2 inhibitor, having well-differentiated or dedifferentiated liposarcoma or intimal sarcoma, or primary malignancies that need antineoplastic treatment within the 2 previous years. If patients had a primary brain tumor, untreated brain metastases, or gastrointestinal conditions they were also excluded. Major surgery within 3 weeks of study treatment, receiving curative-intent radiation therapy within 4 weeks of treatment, or having uncontrolled or significant cardiovascular disease they were excluded from the trial.

“In the first 10 evaluable patients, we have observed activity with 2 unconfirmed partial responses at their first scan and promising tumor regression activity in 2 patients following milademetan monotherapy. In addition, anti-tumor activity was observed in patients with genetic co-alterations, and in tumors with MDM2 copy number above 8. Hence, we plan to revise the protocol to include patients tested locally for MDM2 copy number of 8 and greater. We are encouraged by these preliminary data and we look forward to continuing the trial and evaluating additional data as they become available in the coming months,” Richard Bryce, MBChB, chief medical officer at Rain, concluded.

Reference

Rain Therapeutics provides interim pnalysis of Phase 2 basket trial of milademetan for MDM2-amplified advanced solid tumors (MANTRA-2). News release. Rain Therapeutics, November 4, 2022. Accessed November 7, 2022. https://yhoo.it/3fDWAnD

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.